When was VeGen founded?

VeGen was founded in 2021 and raised its 1st funding round 4 years after it was founded.

Where is VeGen located?

VeGen is headquartered in Hyderabad, India. It is registered at Flat No. 706, Block No.14, My Home Vihanga, TNGO Colony, Financial District, Hyderabad, Telangana, India, 500032.

How many employees does VeGen have?

As of May 31, 2026, the latest employee count at VeGen is 5.

Is VeGen a funded company?

VeGen is a funded company, having raised a total of ₹***** in its 1st and only funding round, a Grant (prize money) round on Mar 03, 2025.

When was the latest funding round of VeGen?

VeGen's latest funding was a ₹***** Grant (prize money) round on Mar 03, 2025, with participation from 1 investor.

What is the annual revenue of VeGen?

Annual revenue of VeGen is less than ₹10 Cr as on Mar 31, 2025

Where does VeGen rank among its competitors?

VeGen ranks 2731st amongst 3260 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of VeGen?

VeGen's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

VeGen - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for cancer patients. It offers a pipeline of drug candidates which include IND126 for lung cancer, colorectal cancer, KRAS12D for pancreatic cancer, and others.

Website: vegen.in
Email ID: *****@vegen.in
Phone Number: +91 **********
Registered Address: Flat No. 706, Block No.14, My Home Vihanga, TNGO Colony, Financial District, Hyderabad, Telangana, India, 500032

Key Metrics

Founded Year

2021

Location

Hyderabad, India

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Mar 03, 2025, ₹*****

Investors

BIRAC

Ranked

2731^st among 3260 active competitors

Annual Revenue

0 - ₹10 Cr as on Mar 31, 2025

Employee Count

5 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2977 more

View VeGen's full profile

VeGen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Vegen Labs Llp CIN: AAX-5981 , India, Active	Jun 30, 2021	0 - ₹10 Cr (As on Mar 31, 2025)	-

VeGen has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Mar 03, 2025 for ₹*****. 1 investor participated in its latest round. VeGen has 1 institutional investor.

Here is the list of recent funding rounds of VeGen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 03, 2025	2139672	Grant (prize money)	5549377	2090168	1615072	4785218

Access funding benchmarks and valuations. Sign up today!

View details of VeGen's funding rounds and investors

The founders of VeGen are Prashant Bhavar and Uday Kumar.

Here are the details of VeGen's key team members:

Prashant Bhavar: Co-Founder of VeGen.
Uday Kumar: Co-Founder of VeGen.

View details of VeGen's Founder profiles and Board Members

VeGen's employee count trend

VeGen has 5 employees as of May 26. Here is VeGen's employee count trend over the years:

Uncover VeGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VeGen include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of VeGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Eight Roads Ventures & 23 others	71/100
2731st	VeGen 2021, Hyderabad (India), Funding Raised	Developer of therapeutics for cancer patients	-	BIRAC	23/100